We bring together biology and technology to enable food producers to improve their sustainability and profitability.
Investment Proposition
High growth markets
Focus on established, fast growing markets of genetics, health and specialist nutrition serving the increasingly important aquaculture sector.
Unique model
Benchmark has a differentiated model bringing together genetics, health and specialist nutrition, which combined can contribute significantly to improve the sustainability and profitability of aquaculture producers.
Barriers to competition
Market leadership, strong patent portfolio, long established breeding programmes and accredited manufacturing capability.
Scalable
Global distribution network and production capacity to support growth.
Potential to deliver high shareholder returns
High growth profile and target 25% EBITDA margin within 3 to five years.
Strategy
- Grow in established markets from existing capacity
- Commercial delivery of AquaHealth pipeline of products
- Focussed investment in markets that leverage group platform
- Position Benchmark in areas of future growth
Share Price (GBX)
Regulatory News
Click the video to watch
Benchmark's Capital Market Day 2018
Financial Calendar
| Date | Title |
|---|---|
| 30 September 2018 | Financial year end |
| October 2018 | Trading update |
| January 2019 | Announcement of full-year results |
| January 2019 | Publication of Annual Report and Accounts |
| March 2019 | Annual General Meeting |
| June 2019 | Announcement of half-year results |
| June 2019 | Publication of Interim Report |
| 30 September 2019 | Financial year end |
Financial Highlights
+9%
Renvenue at H1 2017 forex rate
+16%
revenue increase in Advanced Nutrition
+91%
increase in Adjusted EBITDA
100%
increasing interest in Ectosan; field trials showing 100% efficacy
£75.7m
H1 2017: £69.2m
+11%
revenue increase in Genetics
£6.3m
H1 2017: £3.3m
| £m | H1 2018 | H1 2017 | % | FY 2017 |
|---|---|---|---|---|
| Revenue | 75.7 | 69.2 | +9% | 140.2 |
| EBITDA 1 | 6.3 | 5.2 | +21% | 15.7 |
| Adjusted EBITDA 2 | 6.3 | 3.3 | +91% | 10.0 |
| Adjusted PBT 3 | 4.4 | (0.7) | - | 6.3 |
| Loss before tax | (5.6) | (8.9) | - | (8.1) |
| Profit/(loss) for the period | 3.6 | (8.2) | - | (7.1) |
| Basic earnings/(loss) per share (p) | 0.67 | (1.58) | - | (1.43) |
| Net debt 4 | (41.3) | (12.8) | - | (23.9) |
(2) Adjusted EBITDA is earnings before interest, tax, depreciation, amortisation, exceptional items and acquisition related expenditure
(3) Adjusted PBT is profit/loss before tax, before amortisation, share option charge, exceptional items and acquisition related expenditure
(4) Net debt is cash and cash equivalents less loans and borrowings